“You can’t unring a bell.”
But if your ears have been putting on a private concert nobody bought tickets for, you deserve a better conversation than “there’s no cure.” A prescription device called Lenire pairs headphones with a small contact on your tongue to treat tinnitus symptoms. Yes, your tongue. Your ears have been doing all the complaining, and now another body part has been called into the meeting.
This is wearable treatment technology, rather than a watch trying to assign your ringing a score. You wear the headphones and use the tongue contact during prescribed sessions. Lenire, made by Neuromod, is intended to temporarily relieve tinnitus symptoms in adults with at least moderate tinnitus. Tinnitus can improve, and some cases resolve. That possibility deserves attention without selling this device as a promise to delete the sound.
For Veterans, this conversation has moved beyond a shiny device on somebody’s conference table. Atlanta VA reported its first Lenire use on April 2, 2026. And an October conference report described experience with eight Veterans treated at Houston’s Michael E. DeBakey VA Medical Center. Those are specific places using a specific system. They don’t establish that your local VA stocks it or that it belongs in your care.
What exactly are you wearing?
Lenire uses headphones to deliver sound while its Tonguetip delivers mild electrical stimulation to the surface of the tongue. A handheld controller coordinates the treatment. The combination is called bimodal stimulation: two kinds of stimulation used together. You don’t need to become fluent in medical gadget to understand the practical distinction. Ordinary Bluetooth headphones playing a rainstorm are not the same treatment.
Nor is Lenire a hearing aid. Hearing aids amplify outside sound for people who need that help. Wearable sound generators supply sound, and some hearing aids combine amplification with a sound generator. Those can have a place in tinnitus care too. The useful question is which job you need done. Buying everything that fits near an ear would be an expensive way to avoid answering it.
The FDA granted Lenire De Novo authorization in March 2023 for the defined adult tinnitus indication. Its use requires a prescription from a professional experienced in evaluating and managing tinnitus. That date matters: this is not a device invented last Tuesday. The newer question is what experience in actual Veteran care is teaching us about who benefits and what it takes to complete treatment.
Eight Veterans deserve attention. They don’t represent everybody.
At the October 17, 2026 otolaryngology conference, Samantha Little and colleagues reported a retrospective case series from DeBakey VA. Eight Veterans were included, and seven completed twelve weeks of treatment. The completers had lower tinnitus handicap scores afterward. Improving sleep and managing tinnitus were common goals. That is a small but relevant look at the work Veterans actually want this technology to do.
It was also a conference report looking back at care, without a separate comparison group. It cannot tell us how much improvement the device caused or predict your result. I want to see those early Veteran experiences followed by stronger evidence, not inflated until eight people have somehow become the entire VA. Encouraging is a perfectly useful word. We don’t have to promote it to guaranteed.
The larger TENT-A3 study, published in 2024, enrolled 112 people who received sound first and then sound plus tongue stimulation. Added benefit was reported for the group still experiencing at least moderate tinnitus when the combined treatment began, rather than across the full cohort. Participants served as their own controls; there was no sham comparison. The paper discloses manufacturer funding and author relationships with Neuromod. The useful next question is which Veterans benefit, how much, and whether they can sustain the routine. We ought to be curious enough to investigate it and precise enough to explain what the results mean.
Ask what improvement would mean for you before discussing a success percentage. Sleeping more easily? Being less distracted? Feeling less bothered by the sound? A tinnitus questionnaire can track that burden, but a lower score does not necessarily mean silence. If your goal and the study’s outcome are different things, get that sorted before you start counting treatment days.
Hubert Lim, as a TENT-A3 author and Neuromod’s chief scientific officer, what should a larger Veteran study measure beyond a tinnitus questionnaire? Sleep, daily function and whether people can stick with treatment would be high on my list. Veterans deserve to know what gets better on an ordinary Tuesday, not just what moves on a study chart.
Give the wearable a job you can actually judge
Tell VA Audiology how the problem affects your day, what you have tried, and whether hearing difficulty or sound intolerance is part of the picture. Then ask: “Would Lenire fit my situation, or would hearing aids, a sound generator, or another tinnitus approach make more sense?” You are asking for an evaluation with options. A brand name should help open that conversation, not finish it.
PRO MOVE: Put the treatment on your calendar before putting it in your shopping plans. The pivotal trial used one hour a day for twelve weeks. Ask what routine your clinician would prescribe, whether you can comfortably handle the controller and tongue contact, and how progress or worsening would be reviewed. A wearable that does not fit your life can become a very sophisticated paperweight.
VA’s national Audiology service says enrolled Veterans can schedule directly without a primary care referral. Contact your local VA Audiology clinic and ask about a tinnitus evaluation and the services available there. If Lenire is unavailable, ask what the clinic can offer now, including Progressive Tinnitus Management. That program can involve education and coping skills alongside other care. “We don’t offer that device” should start the next question, not end the entire conversation.
VA Greater Los Angeles’ August account described Air Force Veteran Samantha Block seeking care after everyday sound became overwhelming. Her predominant issue was tinnitus, rather than hearing loss. The report also cited 3,583,295 Veterans receiving tinnitus compensation in 2025. That is a compensation count, not a count of people suited to Lenire. Her experience gives us a better starting question than “Which hearing gadget should I get?” Ask what is making daily life harder.
If tinnitus comes with sudden hearing loss, seek medical care immediately rather than waiting for a routine device appointment. Get prompt medical assessment for pulsing tinnitus, severe dizziness, or other concerning new symptoms. A shopping comparison is the wrong tool for an urgent hearing change.
For the routine conversation, bring one goal and ask how you will know whether the treatment is helping. We can take relief seriously without promising silence, and ask for help without arriving with a product already picked out. Veterans: which answer would help you most before considering this wearable, whether you fit, what the sessions involve, or how the benefit is measured? Audiology teams: what most often changes that first conversation? Lenire’s team: what practical obstacle should Veterans discuss before committing to the routine?
The question for companies bringing treatment technology to VA
For a company, a Veteran asking about a device is the beginning of the work. The care team still needs to know who fits, what training and support are required, and how treatment will be reviewed. JhetVet® helps companies assess that readiness and build a practical VA market and implementation path. If your plan explains how the product gets ordered but leaves the Veteran’s next twelve weeks to somebody else, bring that plan to a conversation with JhetVet®.
Sources and original edition
Adapted from Chet McLendon’s November 10 Assess Your Six™ Newsletter. Device distinctions and symptom education also draw on NIDCD’s tinnitus guidance. The linked FDA order, VA accounts, conference abstract and published trial support different claims; none establishes that a particular local VA clinic will prescribe Lenire for you.
